Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Existing members on the compound version will be transitioned to FDA-approved Wegovy
Important safety information: These medications carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
It is often used by individuals who find it hard to swallow solid dosage forms or for certain age groups such as children and the elderly
Never mix the two compounds in one syringe
Unprecedented Weight Loss In clinical trials, patients taking the highest dose of Retatrutide lost an average of 24.2% of their body weight in 48 weeksgreater than the weight loss seen with existing GLP-1 receptor agonists like semaglutide (Wegovy) and tripeptide (Mounjaro)
